Your session is about to expire
← Back to Search
HPG1860 for Non-alcoholic Fatty Liver Disease (RISE Trial)
RISE Trial Summary
This trial is testing a new medication for NASH, a Liver disease. It's comparing 3 different doses of the medication to placebo, in order to see if the medication is effective.
- Non-alcoholic Fatty Liver Disease (NAFLD)
RISE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRISE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RISE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who is eligible to participate in this clinical investigation?
"This clinical trial is enrolling a cohort of 89 individuals between 18 and 75 years old, who have been diagnosed with fatty liver. In addition to the age requirement, participants must be male or female, employ an effective contraception method for males only; as well as agree to all other restrictions outlined in the study protocol such as BMI ≥ 25 kg/m2 at screening and provide informed consent before any procedures related to this study can occur. Non-pregnant women are also eligible."
Is enrollment in this study ongoing?
"Clinicaltrials.gov indicates that this trial is not presently enrolling patients, although it was originally posted on November 22nd 2021 and revised at the end of September 2022. Fortunately, there are 234 other medical studies actively looking for research participants currently."
Is this experiment open to enrollees aged eighty or higher?
"The parameters for enrollment in this trial dictate that each patient is between 18 to 75 years old. Additionally, there are 22 studies specifically catering towards people younger than 18 and 192 clinical trials targeting individuals above the age of 65."
Could you please elucidate the safety profile of HPG1860?
"Due to the lack of clinical data supporting its efficacy, HPG1860 was scored a 2 in terms of safety. However, there is still some evidence that it can be used safely."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger